Total Payments
$752.60
2024 Payments
$292.88
Companies
10
Transactions
24
Medicare Patients
2,066
Medicare Billing
$420,605
Payment Breakdown by Category
Food & Beverage$734.51 (97.6%)
Education$18.09 (2.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $734.51 | 23 | 97.6% |
| Education | $18.09 | 1 | 2.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $238.79 | 3 | $0 (2024) |
| Abbott Laboratories | $135.58 | 1 | $0 (2024) |
| RedHill Biopharma Inc. | $96.36 | 6 | $0 (2023) |
| Merck Sharp & Dohme LLC | $88.67 | 5 | $0 (2024) |
| Astellas Pharma US Inc | $49.84 | 2 | $0 (2017) |
| ABBVIE INC. | $39.42 | 2 | $0 (2023) |
| Allergan, Inc. | $36.80 | 2 | $0 (2020) |
| Shionogi Inc | $31.79 | 1 | $0 (2022) |
| Melinta Therapeutics, LLC | $21.07 | 1 | $0 (2021) |
| TETRAPHASE PHARMACEUTICALS, INC. | $14.28 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $292.88 | 4 | Abbott Laboratories ($135.58) |
| 2023 | $184.53 | 5 | Boston Scientific Corporation ($130.27) |
| 2022 | $113.31 | 6 | RedHill Biopharma Inc. ($81.52) |
| 2021 | $21.07 | 1 | Melinta Therapeutics, LLC ($21.07) |
| 2020 | $79.94 | 5 | Allergan, Inc. ($36.80) |
| 2019 | $11.03 | 1 | Merck Sharp & Dohme Corporation ($11.03) |
| 2017 | $49.84 | 2 | Astellas Pharma US Inc ($49.84) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Abbott Laboratories | DRAGONFLY OPSTAR (Device) | Food and Beverage | In-kind items and services | $135.58 | General |
| Category: Vascular | ||||||
| 04/25/2024 | Boston Scientific Corporation | ACUITY Steerable (Device) | Food and Beverage | In-kind items and services | $108.52 | General |
| Category: ACUITY_CRM | ||||||
| 04/04/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/07/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $30.69 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/02/2023 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $76.97 | General |
| Category: General - EP_EP | ||||||
| 05/09/2023 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $53.30 | General |
| Category: WATCHMAN_IC | ||||||
| 03/22/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/02/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/23/2023 | RedHill Biopharma Inc. | Talicia (Drug), Movantik, Aemcolo | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Antibiotic | ||||||
| 11/23/2022 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Antibiotic | ||||||
| 10/20/2022 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Antibiotic | ||||||
| 09/20/2022 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Antibiotic | ||||||
| 08/25/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $31.79 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/30/2022 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: Antibiotic | ||||||
| 05/25/2022 | RedHill Biopharma Inc. | Talicia (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Antibiotic | ||||||
| 04/01/2021 | Melinta Therapeutics, LLC | Vabomere (Drug), Orbactiv | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: ANTIBIOTICS | ||||||
| 10/21/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), RECARBRIO | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/16/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/04/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/19/2020 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/12/2020 | TETRAPHASE PHARMACEUTICALS, INC. | XERAVA (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 03/06/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug), SIVEXTRO | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/30/2017 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Infectious Diseases | ||||||
| 02/23/2017 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 549 | 1,790 | $540,646 | $138,263 |
| 2022 | 6 | 480 | 1,318 | $164,008 | $82,662 |
| 2021 | 5 | 493 | 1,595 | $192,104 | $100,621 |
| 2020 | 5 | 544 | 1,489 | $189,333 | $99,059 |
Total Patients
2,066
Total Services
6,192
Medicare Billing
$420,605
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 212 | 1,036 | $247,533 | $63,983 | 25.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 216 | 617 | $221,466 | $55,758 | 25.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 121 | 137 | $71,647 | $18,522 | 25.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 275 | 1,030 | $115,496 | $58,873 | 51.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 138 | 180 | $29,034 | $14,588 | 50.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 30 | $6,894 | $3,031 | 44.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $5,072 | $2,538 | 50.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 31 | $4,722 | $2,228 | 47.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 14 | 31 | $2,790 | $1,405 | 50.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 294 | 1,365 | $151,833 | $79,849 | 52.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 125 | 134 | $21,628 | $11,235 | 51.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 38 | 40 | $12,680 | $6,531 | 51.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 23 | 43 | $3,870 | $1,911 | 49.4% |
| 99226 | Subsequent observation care, typically 35 minutes per day | Facility | 2021 | 13 | 13 | $2,093 | $1,095 | 52.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 314 | 1,226 | $135,844 | $72,101 | 53.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 147 | 152 | $24,441 | $13,088 | 53.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 42 | 43 | $13,411 | $7,078 | 52.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 26 | 53 | $11,351 | $4,506 | 39.7% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2020 | 15 | 15 | $4,286 | $2,287 | 53.4% |
About Dr. Syed Hasan, MD
Dr. Syed Hasan, MD is a Infectious Disease healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750450342.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Syed Hasan, MD has received a total of $752.60 in payments from pharmaceutical and medical device companies, with $292.88 received in 2024. These payments were reported across 24 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($734.51).
As a Medicare-enrolled provider, Hasan has provided services to 2,066 Medicare beneficiaries, totaling 6,192 services with total Medicare billing of $420,605. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Houston, TX
- Active Since 11/07/2006
- Last Updated 10/15/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1750450342
Products in Payments
- DRAGONFLY OPSTAR (Device) $135.58
- ACUITY Steerable (Device) $108.52
- Talicia (Drug) $96.36
- AVYCAZ (Drug) $53.97
- WATCHMAN Access System (Device) $53.30
- Cresemba (Drug) $49.84
- PREVYMIS (Drug) $48.78
- Fetroja (Drug) $31.79
- ZERBAXA (Drug) $26.89
- DALVANCE (Drug) $22.25
- Vabomere (Drug) $21.07
- XERAVA (Drug) $14.28
- DIFICID (Drug) $13.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Houston
Dr. Richard Hamill, M.d, M.D
Infectious Disease — Payments: $883,001
Infectious Disease $883,001
Roy Chemaly, M.d, M.D
Infectious Disease — Payments: $815,305
Infectious Disease $815,305
Dr. Joseph Gathe, M.d, M.D
Infectious Disease — Payments: $774,683
Infectious Disease $774,683
Ben Barnett, M.d, M.D
Infectious Disease — Payments: $515,688
Infectious Disease $515,688
Dr. Amar Safdar, M.d, M.D
Infectious Disease — Payments: $309,168
Infectious Disease $309,168
Dr. Luis Ostrosky, M.d, M.D
Infectious Disease — Payments: $242,843
Infectious Disease $242,843